CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI ® is ...

Too many CIOs wire systems together and hope for value; real integration works when business goals, data and resilience come ...